MiP: Successful Sale of MiP's Sterile Production Facility to FAMAR Group

PharmaVentures, a leading M&A advisory firm, acted as the exclusive advisor to the private equity firm capiton AG during the sale of MiP Pharma's sterile production facility located in Homburg, Germany, to the FAMAR Group. FAMAR, a globally operating pharmaceutical and cosmetic contract development and manufacturing company (CDMO), acquired the facility to enhance its supply chain capabilities, reflecting growing demand in the pharmaceutical services sector. This divestment was part of MiP Pharma's strategic plan, aiming to leverage its transformed state-of-the-art production site to advanced manufacturing status under capiton's ownership. Soren Demin, Head of M&A at PharmaVentures, emphasized the success of the transaction in fulfilling MiP's strategic plans while enabling FAMAR to access growth opportunities. Dr. Fintan Walton, CEO of PharmaVentures, highlighted the vital role of specialized advisors in executing these transformative deals, further showcasing PharmaVentures' proficiency in the pharmaceutical services industry. Capitol AG, an independent private equity firm with a fund volume of €1.6 billion, supports medium-sized companies in management buy-outs and growth financing. This transaction contributes to the ongoing evolution and consolidation within the pharmaceutical services industry and underscores the significance of utilizing expert advisory services for executing complex M&A transactions.